当前位置:循环首页>正文

EuroPCR2023,精彩前瞻,Late-Breaking内容一览

作者:国际循环网   日期:2023/5/10 16:01:38

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

2023年欧洲介入心脏病学大会(EuroPCR)将于2023年5月16日至19日在法国巴黎举行。EuroPCR是全球三大介入治疗会议之一,是世界范围内最具影响力的心脏介入大会之一。超过114个国家的万余名心脏介入医生将在本次大会上交流碰撞,《国际循环》将本次大会上的重要讲题汇总整理,方便各位相关读者及时了解讯息。

 

最新临床数据:关注左主干和分叉病变PCI

Late-Breaking clinical data: focus on left main and bifurcation PCI

时间:5月16日  12:00-13:30

地点:ROOM MAILLOT

 

EBC TWO five-year follow-up - Provisional vs. culotte for coronary bifurcations

EBC TWO试验5年随访:冠脉分叉病变Provisional与 culotte策略的比较

S. Arunothayaraj

 

Provisional stenting in bifurcation lesion: benefit of side branch intervention?

冠脉分叉病变Provisional策略:侧枝介入的获益?

B. Chevalier

 

iFR vs. FFR-guided revascularisation decision-making in left main disease

iFR 与 FFR引导的左主干病变血运重建的策略制定

T. Warisawa

 

Impact of residual ischaemia after left main bifurcation stenting on cardiovascular mortality

左主干分叉支架术后残余缺血对心血管死亡率的影响

B. Xu

 

The European Bifurcation Club left main coronary stent study: three-year follow-up

欧洲分叉俱乐部左主干冠脉支架研究:3年随访

D. Hildick-Smith

 

Dynamic coronary roadmap for contrast reduction trial

对比降低试验的动态冠状动脉路线图

J. Escaned

 

最新临床数据:TAVI

Late-Breaking clinical data: TAVI

时间:5月16日 15:00 - 16:30

地点:ROOM MAILLOT

 

Outcomes of repeat TAVR with balloon-expandable valves

球囊扩张瓣膜复做TAVR的结果

R. Makkar

 

Five-year outcomes with the Acurate neo2 valve: the Neo AS CE-mark study

Acurate neo2瓣膜的五年结果:Neo AS CE-mark研究

H. Möllmann

 

TAVR in patients with cardiogenic shock: TVT-registry analysis

心源性休克患者的TAVR:TVT-注册分析

A. Dhoble

 

Five-year outcomes for TAVI with an intra-annular, self-expandable bioprosthesis

使用环内自膨胀生物假体TAVI的五年结果

L. Sondergaard

 

Chimney stenting vs. BASILICA to prevent TAVR-related coronary obstruction

烟囱支架技术与瓣叶切割技术(BASILICA)预防TAVR相关冠状动脉阻塞的比较

A. Mangieri

 

INTERCEPTavi: carbon-dioxide flushing reduces vascular brain injury in TAVI

INTERCEPTavi: 二氧化碳冲洗减少TAVI的血管性脑损伤

S.A. Khawaja

 

PORTICO IDE trial: five-year outcomes of Portico vs. commercially available valves

PORTICO IDE 试验:Portico与市售瓣膜的五年结果

R. Makkar

 

最新临床数据:二尖瓣和三尖瓣疾病

Late-Breaking clinical data: mitral and tricuspid valves disease

时间:5月17日  08:30 - 10:00

地点:ROOM MAILLOT

 

Early experience with a d-shape, monoleaflet TMVR system

d形单叶TMVR系统的早期经验

S. Salizzoni

 

Outcomes of Mitral Valve-in-Valve, Mitral Valve-in-Ring and Valve-in-Mitral Annular Calcification: prospective MITRAL (Mitral Implantation of TRAnscatheter vaLves) trial final results

瓣膜内二尖瓣、环内二尖瓣和二尖瓣环内瓣膜钙化的结果:前瞻性MITRAL(经导管瓣膜的二尖瓣植入)试验最终结果

M. Guerrero

 

DRAGONFLY-DMR: transcatheter repair by DragonFly device in mitral regurgitation

DRAGONFLY-DMR试验:经导管DragonFly系统治疗二尖瓣反流

S. Lim

 

Outcomes of TMVR vs. medical therapy for secondary mitral regurgitation

经导管二尖瓣置换术(TMVR)与药物治疗继发性二尖瓣反流的疗效比较

S. Ludwig

 

HighLife transseptal mitral valve replacement: first-in-man primary end-point outcomes

HighLife经中隔二尖瓣置换术:首次人体实验的主要终点结果

S. Worthley

 

Real-world outcomes for TEER: 30-day results from the TriClip bRIGHT study

TEER的真实世界结果: TriClip bRIGHT研究的30天结果

P. Lurz

 

TRILUMINATE Pivotal: randomised trial of TEER for tricuspid regurgitation

TRILUMINATE Pivotal: TEER治疗三尖瓣反流的随机试验

P. Sorajja

 

最新临床数据:TAVI、高血压、卒中预防

Late-Breaking clinical data: TAVI,hypertension, stroke prevention

时间:5月17日  10:30 - 12:00

地点:ROOM MAILLOT

 

Primary outcome of the AnchorMan LAAO device randomised controlled trial (SAFE-PROTECT trial)

AnchorMan LAAO(左心耳封堵)系统随机对照试验 (SAFE-PROTECT 试验)主要结果

B. He何奔

 

Low dose direct oral anticoagulation vs. DAPT after LAAO

LAAO后小剂量直接口服抗凝与DAPT的比较

X. Freixa

 

Pivotal trial of targeted renal denervation to treat hypertension: SMART study

靶向去肾神经治疗高血压的关键试验:SMART研究

J. Wang王捷

 

Efficacy and safety of the Netrod radiofrequency renal denervation system

Netrod射频去肾神经系统的有效性和安全性

F. Gao高霏

 

Randomised study evaluating an intervention reducing length of stay after TAVI

评价减少TAVI后住院时间的干预措施的随机研究

E. Durand

 

BENCHMARK: streamlined TAVI pathway with retained safety in 28 European centres

BENCHMARK试验:在28个欧洲中心保持安全性的简化TAVI路径

D. Frank

 

最新临床数据:聚焦支架技术

Late-Breaking clinical data: focus on stent technology

时间:5月17日  14:45 - 16:15

地点:ROOM MAILLOT

 

12-month primary endpoint outcomes of the BIOADAPTOR-RCT

BIOADAPTOR-RCT:12个月主要终点结果

S. Saito

 

Final five-year results from the blinded ABSORB IV trial

盲法ABSORB IV试验最终5年结果

G. Stone

 

BIOMAG-I: one-year clinical outcome of the resorbable magnesium scaffold-DREAMS 3G

BIOMAG-I:可吸收镁支架-DREAMS 3G的1年临床结果

M. Haude

 

Long-term outcome after resorbable magnesium scaffold implantation

植入可吸收镁支架后的长期结果

G. Pompei

 

Biodegradable polymer vs. polymer-free ultrathin sirolimus-eluting stents

可生物降解聚合物与无聚合物超薄西罗莫司洗脱支架的比较

H.S. Kim

Clinical outcomes at three years from first-in-man LEADERS FREE III trial

首次人体试验 LEADERS FREE III研究的 3年临床结果

F. Eberli

 

Randomised trial of biolimus DEB for in-stent restenosis: the REFORM study

REFORM 研究:西罗莫司药物洗脱支架支架内再狭窄的随机试验

R. Byrne

 

最新临床数据:关注导丝和基于影像的生理学

Late-Breaking clinical data: focus on wire and image-based physiology

时间:5月18日  15:15 - 16:45

地点:ROOM MAILLOT

 

Coronary microvascular function and CT coronary angiography trial

冠状动脉微血管功能和CT冠状动脉造影试验

N. Sidik

 

DEFINE-FLAIR: five-year follow-up

DEFINE-FLAIR: 5年随访

J. Escaned

 

FFR in chronic coronary syndrome: a report from SCAAR

血流储备分数(FFR)在慢性冠状动脉综合征(CCS)中的应用:来自SCAAR的报告

S. Buccheri

 

FFR-guided PCI vs. CABG - Three-year follow-up of the randomised FAME 3 trial

FFR引导的 PCI 与CABG的比较 :FAME 3试验3年随访

F. Zimmermann

 

Prognostic value of post-PCI QFR in the randomized FLAVOUR trial

FLAVOUR试验中PCI术后QFR的预后价值

S. Tu涂圣贤

 

Accuracy of instantaneous wave-free ratio derived from coronary angiography

冠状动脉造影瞬时无波比(iwr)的准确性

Y. Onuma

 

临床热线:从STEMI/ N-STEMI到慢性冠状动脉综合征

Clinical Hotline: from (N)STEMI to Chronic Coronary Syndromes (CCS)

时间:5月19日  08:30 - 10:00

地点:ROOM MAILLOT

 

Selective Intracoronary hypothermia in anterior wall myocardial infarction

选择性冠状动脉内低温治疗前壁心肌梗死

N. Pijls

 

Real-time catheter-based microvascular obstruction detection in STEMI: results from the MOCA I study

基于导管的STEMI中实时微血管阻塞检测:来自MOCA I研究的结果

M. Valgimigli

 

QFR vs. FFR in STEMI: a substudy of the REDUCE MVI randomised clinical trial

QFR vs. FFR在STEMI中:REDUCE MVI随机临床试验亚组研究

L. Wang

 

Immediate culprit lesion primary PCI in patients with STEMI

STEMI患者罪犯病变的即刻初次PCI

N. Levi

 

Extracorporeal membrane oxygenation vs. standard care in cardiogenic shock

体外膜肺氧合与心源性休克的标准治疗

M. Sabate

 

Five-year clinical outcome of a the TIDES ACS study

TIDES ACS研究5年临床结果

F. Bouisset

 

Murray law-based QFR on three-year outcomes of FORZA trial

基于默里定律的QFR对FORZA试验3年结果的评价

C. Aurigemma

 

Quantitative flow ratio or angiography for the assessment of non-culprit lesions

定量血流比(QFR)或血管造影术用于评估非罪魁祸首病变

T. Gori

 

PCI or bypass surgery for multivessel coronary disease in diabetic population

PCI或旁路手术治疗糖尿病人群冠脉多支病变

J.M. Ahn

 

Non-cardiac mortality with elective revascularisation vs. medical therapy

择期血运重建与药物治疗的非心脏死亡率比较

E. Navarese

版面编辑:张冉  责任编辑:彭龙妹


EuroPCR2023

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530